Your browser doesn't support javascript.
loading
[The efficacy and safety of low-dose chemotherapy combined with tyrosine kinase inhibitors in the treatment of Philadelphia-chromosomal-positive acute lymphoblastic leukemia].
Wang, H; Zhao, T; Hu, L J; Li, Z R; Jiang, H; Qin, Y Z; Lai, Y Y; Shi, H X; Huang, X J; Jiang, Q.
Afiliação
  • Wang H; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China Wang Huan is working on the Beijing Chuiyangliu Hospital, Beijing 100021, China.
  • Zhao T; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Hu LJ; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Li ZR; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Jiang H; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Qin YZ; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Lai YY; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Shi HX; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Huang XJ; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
  • Jiang Q; Beijing University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
Zhonghua Xue Ye Xue Za Zhi ; 43(7): 550-556, 2022 Jul 14.
Article em Zh | MEDLINE | ID: mdl-36709131
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Adolescent / Adult / Aged / Child / Humans / Middle aged Idioma: Zh Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Leucemia-Linfoma Linfoblástico de Células Precursoras Limite: Adolescent / Adult / Aged / Child / Humans / Middle aged Idioma: Zh Ano de publicação: 2022 Tipo de documento: Article